Symptomatic Patients With Myelofibrosis Treated Post-JAK Inhibition

Transfusion Independence With Momelotinib Impacts OS in Myelofibrosis

During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed dosing of JAK inhibitors therapy and how the survival data for ruxolitinib compares with that of momelotinib. This is the second of 2 articles based on this event.

Importance of Early Start to Therapy and SCT Referral in Myelofibrosis

During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed approaches to starting JAK inhibitor therapy for a patient with myelofibrosis and when to refer for stem cell transplant. This is the first of 2 articles based on this event.

Trials Support Use of Momelotinib After JAK Inhibition for Anemic MF

During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed data from the SIMPLIFY-2 and MOMENTUM trials of momelotinib for patients with myelofibrosis. This is the second of 2 articles based on this event.

Dosing and Assessing Patients Receiving JAK Inhibitor for Myelofibrosis

During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed the case of a patient with myelofibrosis who was treated with ruxolitinib but showed signs of progression. This is the first of 2 articles based on this event.

Momelotinib Impacts Treatment Methods for Anemia in Myelofibrosis

Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.